Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

Thorax

Volumn 68, Issue 9, 2013, Pages 818-825

  Clancy, J P ^a   Dupont, L ^b   Konstan, M W ^c   Billings, J ^d   Fustik, S ^e   Goss, C H ^f   Lymp, J ^g   Minic, P ^h   Quittner, A L ⁱ   Rubenstein, R C ^j   Young, K R ^k   Saiman, L ^l   Burns, J L ^f   Govan, J R W ^m   Ramsey, B ^f   Gupta, R ⁿ  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Clinical Centre   (Macedonia)

^f UNIVERSITY OF WASHINGTON   (United States)

^g SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^h Institute for Mother and Child Health Care   (Serbia)

ⁱ Department of Biology   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k ALBERT EINSTEIN MEDICAL CENTER   (United States)

^l Och Spine at New York Presbyterian Hospitals   (United States)

^m UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁿ Insmed Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ARIKACE; LIPOSOMAL AMIKACIN; PLACEBO; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; LIPOSOME;

ABNORMAL RESPIRATORY SOUND; ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; BODY MASS; CHILL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUALITY OF LIFE QUESTIONNAIRE REVISED; DENSITY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMATOMA; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; KIDNEY CLEARANCE; LARYNGITIS; LIVER FUNCTION TEST; LUNG CONGESTION; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEBULIZATION; NONHUMAN; OUTCOME ASSESSMENT; PARANASAL SINUS DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUESTIONNAIRE; RALES; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT DISEASE; RESPIROMETRY; RHINORRHEA; RHONCHI; SIDE EFFECT; SINUS CONGESTION; SINUSITIS; SORE THROAT; SPUTUM ANALYSIS; THROAT TIGHTNESS; TINNITUS; TREATMENT DURATION; VESSEL PUNCTURE SITE HEMATOMA; WHEEZING; ANALYSIS OF VARIANCE; CHILD; CLINICAL TRIAL; COMPLICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEBULIZER; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; SPUTUM; YOUNG ADULT;

ADOLESCENT; ADULT; AMIKACIN; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LIPOSOMES; MALE; MICROBIAL SENSITIVITY TESTS; NEBULIZERS AND VAPORIZERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; SPUTUM; YOUNG ADULT;

EID: 84881542878     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202230     Document Type: Article

References (26)

1. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science (New York, NY) 1989;245:1059-65. (Pubitemid 19231813)
2. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science (New York, NY) 1989;245:1073-80. (Pubitemid 19231815)
3. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001. (Pubitemid 40638370)
4. Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 2007;28:279-88. (Pubitemid 46661880)
5. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8. (Pubitemid 40171240)
6. Dasenbrook EC, Merlo CA, Diener-West M, et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178:814-21.
7. Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303:2386-92.
8. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
9. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63. (Pubitemid 34114228)
10. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8.
11. Oermann CM, Assael B, Nakamura C, et al. Poster: Aztreonam for Inhalation Solution (AZLI) vs. Tobramycin Inhalation Solution (TIS): a 6-month Comparative Trial in Cystic Fibrosis (CF) Patients with Pseudomonas aeruginosa (PA). Pediatr Pulmonol 2010;45(Supplement 33)(abs 305):327.
12. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-32.
13. Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68:344-50.
14. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-34.
15. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011;10:54-61.
16. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J Cyst Fibros 2013;12:130-40.
17. Coates AL. Performance of PARI eFlow. J Aerosol Med Pulm Drug Deliv 2010;23:114; author reply -8.
18. Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61:859-68. (Pubitemid 351426071)
19. Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008;21:245-54.
20. Clancy JP. Clinical Trials of Lipid-Associated Aerosolized Amikacin: the ArikaceTM Story. Pediatr Pulmonol 2009;44:109-212.
21. Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009;22:131-8.
22. Chinoy MR, Fisher AB, Shuman H. Confocal imaging of time-dependent internalization and localization of NBD-PC in intact rat lungs. Am J Physiol 1994;266(6 Pt 1):L713-21.
23. Martini WZ, Chinkes DL, Barrow RE, et al. Lung surfactant kinetics in conscious pigs. Am J Physiol 1999;277(1 Pt 1):E187-95.
24. Babiker A, Andersson O, Lindblom D, et al. Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. J Lipid Res 1999;40:1417-25. (Pubitemid 29379981)
25. Diczfalusy U, Lund E, Lutjohann D, et al. Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. Scand J Clin Lab Invest Suppl 1996;226:9-17. (Pubitemid 27018881)
26. Neville M, Liu S, Artis C, et al. Functionality of Foamy Alveolar Macrophages After Inhalation of Aerosolized Liposomal Amikacin (ArikaceTM). Pediatric Pulmonology 2009;44:109-212.